Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results

Last week, you might have seen that SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) released its quarterly result to the market. The early response was not positive, with shares down 6.1% to €23.10 in the past week. The result was positive overall - although revenues of €256m were in line with what the analysts predicted, SCHOTT Pharma KGaA surprised by delivering a statutory profit of €0.30 per share, modestly greater than expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Following the latest results, SCHOTT Pharma KGaA's eleven analysts are now forecasting revenues of €1.10b in 2026. This would be a notable 13% improvement in revenue compared to the last 12 months. Per-share earnings are expected to soar 23% to €1.20. Before this earnings report, the analysts had been forecasting revenues of €1.11b and earnings per share (EPS) of €1.21 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

See our latest analysis for SCHOTT Pharma KGaA

There were no changes to revenue or earnings estimates or the price target of €29.38, suggesting that the company has met expectations in its recent result. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic SCHOTT Pharma KGaA analyst has a price target of €36.00 per share, while the most pessimistic values it at €22.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await SCHOTT Pharma KGaA shareholders.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the SCHOTT Pharma KGaA's past performance and to peers in the same industry. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 10% growth on an annualised basis. That is in line with its 9.9% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 10% annually. So although SCHOTT Pharma KGaA is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for SCHOTT Pharma KGaA going out to 2027, and you can see them free on our platform here..

You can also view our analysis of SCHOTT Pharma KGaA's balance sheet, and whether we think SCHOTT Pharma KGaA is carrying too much debt, for free on our platform here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.